ABSTRACT
BACKGROUND: In humans geographical differences in the incidence and presentation of various cancers have been reported. However, much of this information has not been collected in veterinary oncology. AIM: The purpose of this study was to determine if a geographic difference in progression free survival exists for dogs with lymphoma treated within the US. MATERIALS AND METHODS: Medical records of 775 cases of canine lymphoma from 3 US regions (west, south and north), treated with CHOP chemotherapy, were retrospectively evaluated. Cases were collected from referral institutions and were required to have received at least one doxorubicin treatment and have follow up information regarding time to progression. RESULTS: Significant differences in sex (p = 0.05), weight (p = 0.049), stage (p < 0.001), immunophenotype (p = <0.001), and number of doxorubicin doses (p = 0.001) were seen between regions. Upon univariate analysis, progression free survival (PFS) differed by region (p = 0.006), stage (p = 0.009), sub-stage (p = 0.0005), and immunophenotype (p = 0.001). A multivariable Cox regression model showed that dogs in the western region had a significantly shorter PFS when compared to the south and east. CONCLUSION: PFS was significantly affected by stage, sub-stage and phenotype.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Lymphoma, Non-Hodgkin/veterinary , Animals , Cyclophosphamide/therapeutic use , Dog Diseases/mortality , Dogs , Doxorubicin/therapeutic use , Female , Geography, Medical , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/mortality , Male , Prednisone/therapeutic use , Retrospective Studies , Survival Analysis , United States/epidemiology , Vincristine/therapeutic useABSTRACT
The purpose of this study was to describe the toxicity profile of toceranib phosphate in tumour bearing cats. Medical records were reviewed from seven institutions. Patients with incomplete medical records and those receiving concurrent chemotherapy or NSAIDs (non-steroidal anti-inflammatory) were excluded. Fifty-five cats met the inclusion criteria. Carcinoma was diagnosed in 55% of cases. Median oral toceranib dose was 2.7 mg kg-1 and was most commonly administered on Monday, Wednesday and Friday. Thrombocytopenia (16.3%) and neutropenia (9.1%) were the most common haematologic toxicities. Azotemia (14.5%) and alanine aminotransferase (ALT) elevations (7.2%) were the most frequently encountered biochemical alterations. Gastrointestinal (GI) toxicity was seen in 21.8% of cats, and was lower than previously reported in dogs. The results of this study showed that treatment of cats with toceranib is well-tolerated and toxicity is uncommon. Additional studies to define a more structured dosing schedule and to evaluate the efficacy of toceranib in the treatment of feline cancers are needed.
Subject(s)
Antineoplastic Agents/toxicity , Indoles/toxicity , Pyrroles/toxicity , Alanine Transaminase/blood , Animals , Antineoplastic Agents/therapeutic use , Azotemia/chemically induced , Azotemia/veterinary , Cat Diseases/drug therapy , Cats , Female , Gastrointestinal Tract/drug effects , Indoles/therapeutic use , Male , Neoplasms/drug therapy , Neoplasms/veterinary , Neutropenia/chemically induced , Neutropenia/veterinary , Pyrroles/therapeutic use , Retrospective Studies , Thrombocytopenia/chemically induced , Thrombocytopenia/veterinaryABSTRACT
Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle. The overall response rate (ORR) to the MOMP protocol was 51.1% for a median of 56 days (range 7-858 days). Twelve percent of dogs experienced a complete response for a median of 81 days (range 42-274 days) and 38.6% experienced a partial response for a median of 49 days (range 7-858 days). Dogs with T-cell lymphoma had an ORR of 55% for a median of 60 days (range 49-858 days) while those with B-cell lymphoma had an ORR of 57% for a median of 81 days (range 7-274 days) (P = 0.783). The overall survival time for all dogs was 183 days (range 17-974 days). Fifty-four percent of dogs experienced toxicity with the majority classified as grade I. The MOMP protocol seems well-tolerated and is an option for dogs with relapsed lymphoma.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Lymphoma/veterinary , Mechlorethamine/administration & dosage , Melphalan/administration & dosage , Prednisone/administration & dosage , Vincristine/administration & dosage , Animals , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Dog Diseases/mortality , Dogs , Female , Lymphoma/drug therapy , Lymphoma/mortality , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/mortality , Lymphoma, B-Cell/veterinary , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/mortality , Lymphoma, T-Cell/veterinary , Male , Mechlorethamine/therapeutic use , Melphalan/therapeutic use , Prednisone/therapeutic use , Recurrence , Survival Analysis , Vincristine/therapeutic useABSTRACT
This prospective study evaluated the utility of bone marrow aspirates (BMAs) obtained from multiple sites for staging of canine lymphoma (LSA) and mast cell tumours (MCTs). Forty dogs (LSA, n = 24; MCTs, n = 16) were enrolled, but only 33 (82.5%) had diagnostic bone marrow (BM) aspirates obtained from two sites for inclusion in the study. Nineteen dogs with LSA were included, and 6 (31.6%) had BM involvement. Neoplastic lymphocytes were present in BM from both sites in all of these dogs. Fourteen dogs with MCTs were included, and 3 (21.4%) had BM involvement. Neoplastic mast cells were present at both sites in two dogs and at only one site in the third. These results indicate that BMAs from multiple sites may not be needed for accurate staging of canine LSA patients, but more studies evaluating the pattern of BM infiltration in dogs with high-grade MCTs are warranted.
